Roche

@Roche · Basel, Switzerland · joined 13 Feb 2009

We advance science so that we all have more time with the people we love. Read our community guidelines: https://t.co/7k1HdbdrYL

237 355Followers

219Following

14 815Posts total

18.8KViews on collected posts

Against accounts of the same size

12 posts from the last 90 days, next to the 100K–1M follower range. below its peers on both reach and engagement.

Median views380this account5 994median for 100K–1M

Reach, %0.16%this account2.51%median for 100K–1M

Engagement, %0.58%this account1.40%median for 100K–1M

Metric	This account	Median for 100K–1M	Ratio
Median views per post	380	5 994	0.06×
Reach (views ÷ followers)	0.16%	2.51%	0.06×
Engagement rate	0.58%	1.40%	0.41×

Others in this range → Compare with another account → How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

3.8K20 Jul

187

129

259

50021 Jul

2.7K23 Jul

3.1K24 Jul

4.8K17 Aug

4821 Aug

3.1K28 Aug

Last 12 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.74%20 Jul

1.43%

0.53%

0.78%

1.16%

0.40%21 Jul

0.62%23 Jul

0.71%24 Jul

0.48%17 Aug

0.00%

0.00%21 Aug

0.29%28 Aug

Reactions — likes, reposts, replies and quotes — divided by views. Median for 100K–1M accounts is 1.40%.

What the audience does

Likes67.5%77 in total

Reposts8.8%10 in total

Replies16.7%19 in total

Quotes0.9%1 in total

Bookmarks6.1%7 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Latest posts

#MEDIA – At #APVRS2026, we're pleased to share new two-year data for our treatment in patients with PCV, a severe sub-type of nAMD – the leading cause of vision loss in people over 60. https://t.co/9XpS4N4WXT https://t.co/0pB6w4ulTo 3.1K views · 9 likes · 0 reposts · 0 replies 28 Aug 2026 @Roche #3 https://t.co/2PMukjJ0g2 48 views · 0 likes · 0 reposts · 0 replies 21 Aug 2026 @Roche The real test may be whether predictive systems reduce overnight burden without adding alarm fatigue. How are you measuring that trade-off in real-world use? Sci-Quest generates biomedical literature reviews too: https://t.co/AMUYFvZ8PU 14 views · 0 likes · 0 reposts · 0 replies 17 Aug 2026 Sleep should be a time of rest, not a time of risk. "I think predictive technology gives us a lot more than just a safe sleep and better predictions. It also means more quality of life and not using this energy for the diabetes, but actually using it for things that matter to h 4.8K views · 16 likes · 2 reposts · 5 replies 17 Aug 2026 #MEDIA – We are pleased to share that the CHMP has recommended approval of our continuous delivery treatment for adults with neovascular age-related macular degeneration (#nAMD) - the leading cause of blindness in people over 60. 👉 https://t.co/XQSDUcT8Ji https://t.co/zEQReo8Lva 3.1K views · 16 likes · 1 reposts · 5 replies 24 Jul 2026 Roche continues strong momentum with 6% sales growth (CER) in the first half of 2026 – full-year outlook confirmed. For more details on our performance, click here ➡️ https://t.co/Sa7wnKCwvT https://t.co/Dmfktth0Py 2.7K views · 12 likes · 2 reposts · 3 replies 23 Jul 2026 @leenaaridi Thanks for highlighting this, @leenaaridi ! We’re committed to helping drive progress through advanced sequencing technology and scientific collaboration. Ana at team Roche 500 views · 2 likes · 0 reposts · 0 replies 21 Jul 2026 @juhyungleyhe Thanks for highlighting this, @juhyungleyhe ! We’re committed to helping drive progress through advanced sequencing technology and scientific collaboration. Ana at team Roche 259 views · 2 likes · 1 reposts · 0 replies 20 Jul 2026 @juhyungleyhe Thanks for highlighting this, @juhyungleyhe ! We’re committed to helping drive progress through advanced sequencing technology and scientific collaboration. Ana at team Roche 129 views · 1 likes · 0 reposts · 0 replies 20 Jul 2026 @eyegenedrb Thanks for highlighting this, Jordan ! We’re committed to helping drive progress through advanced sequencing technology and scientific collaboration. Ana at team Roche 187 views · 1 likes · 0 reposts · 0 replies 20 Jul 2026 @Roche What is the breakthrough? 70 views · 1 likes · 0 reposts · 0 replies 20 Jul 2026 Roche’s sequencing by expansion (SBX) technology is transforming DNA sequencing! By converting nucleotide bases into long molecules before it passes through microscopic pores, it scales up molecular signals into digital data.✨ #Biotech #Innovation https://t.co/P4NOhxj8Ub https: 3.8K views · 17 likes · 4 reposts · 6 replies 20 Jul 2026